Navigation Links
Pharmaxis' Aridol Gains First Asian Approval
Date:1/16/2008

SYDNEY, Jan. 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the Korean regulatory agency has granted marketing approval for its asthma management product, Aridol.

"This is the first Asian approval of Aridol," said Pharmaxis Chief Executive Officer Dr Alan Robertson. "Korea is an important base from which to launch and grow Aridol in Asia. There are an estimated 2.5 million asthma sufferers and yet only 160,000 bronchial challenge tests are performed annually to assist with asthma diagnosis and management. The existing broad acceptance of lung function challenge tests presents a firm opportunity for marketing Aridol."

Approval by the Korean regulatory agency was based on the Australian approval and was completed efficiently in just six months.

The Korean pharmaceutical market is one of the twenty largest in the world and together with its Korean distributor BL&H Co Ltd, Pharmaxis will now commence pre-marketing while seeking reimbursement approval through the national health scheme.

The approval process is expected to conclude in the third quarter of 2008.

A simple to use airways inflammation test, Aridol is administered as a dry powder in a hand held inhaler. Doctors can use the results of this test to identify airway hyper-responsiveness -- a hallmark of asthma.
To find out more about Pharmaxis go to http://www.pharmaxis.com.au .

To find out more about Aridol go to http://www.aridol.info .

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission."

CONTACT:

Alan Robertson, Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgroup.com

Australia:

Felicity Moffatt

Tel: +61-418-677-701

Email: moffattf@healthpr.com


'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Phase III Trial Finds Pharmaxis Bronchitol Effective
2. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
3. Pharmaxis Closes Share Purchase Plan
4. Pharmaxis Appoints Portuguese Distributor for Aridol
5. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
7. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
8. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
9. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. N-Viro International Corporation Announces Dismissal of Lawsuit Against It
11. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/24/2017)... ... 24, 2017 , ... It is well established that ligand ... broad application of this cellular target engagement concept to drug discovery has been ... stabilization assays are valuable methods for particular applications, but they can require target-specific ...
(Date:4/21/2017)... ... 2017 , ... The University of Connecticut, in partnership with ... startups through the UConn Innovation Fund. The $1.5 million UConn Innovation Fund was ... , The UConn Innovation Fund provides investments of up to $100,000 to companies ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative ... range of emerging technology-based businesses, recently earned a $77,518 grant from the Rural ... Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI is ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):